Security key
17331Y109
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 105,008
- Total 13F value
- $97,657
- Share change
- -95,876
- SEC-reported price per share
- $0.93
- Number of holders
- 6
- Value change
- -$115,519
- Number of buys
- 2
- Number of sells
- 6
- Shares outstanding
- 93,629,159
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2025
Institutions
6
Top holders
6
CTOR full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2025
CITIUS ONCOLOGY, INC. SEC filings
CITIUS ONCOLOGY, INC. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 17331Y109
Recent filing periods:
Ownership snapshot
Top reported holders of CTOR - CITIUS ONCOLOGY, INC. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Citius Pharmaceuticals, Inc.
Disclosed value leader
HRT FINANCIAL LP
Comparable rows
0/14
Latest evidence
31 Dec 2024
3/4/5
13F
Highest disclosed value: $78,000
14 rows are not safely comparable across share classes.
Showing 1-6 of 14 holder rows.
Quick read
HRT FINANCIAL LP has the largest disclosed position value at $78K.
0 of 14 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens HRT FINANCIAL LP's linked filing trail.
Disclosed position value
Top 5
HRT FINANCIAL LP
$78K
UBS Group AG
$28.5K
CITADEL ADVISORS LLC
$26.1K
IFP Advisors, Inc
$25.5K
XTX Topco Ltd
$24.3K
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-6 of 14 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Citius Pharmaceuticals, Inc. |
3/4/5
10%+ Owner
|
—
denominator unverified
|
—
65,627,262 shares
|
— | 12 Aug 2024 |
| Dahe Zhang |
3/4/5
Chief Financial Officer, Director, 10%+ Owner
|
—
denominator unverified
|
—
1,725,000 shares
|
— | 13 Oct 2022 |
| Xiaofeng Yuan |
3/4/5
Chief Executive Officer, Director, 10%+ Owner
|
—
denominator unverified
|
—
1,725,000 shares
|
— | 13 Oct 2022 |
| HRT FINANCIAL LP |
13F
Company
|
—
denominator unverified
|
$78,000
68,543 shares
|
— | 31 Dec 2024 |
| UBS Group AG |
13F
Company
|
—
denominator unverified
|
$28,526
24,805 shares
|
— | 31 Dec 2024 |
| CITADEL ADVISORS LLC |
13F
Company
|
—
denominator unverified
|
$26,104
22,699 shares
|
— | 31 Dec 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
6
Shares
105,008
Rows available
6
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2025 vs Q2 2026 Across Filers
Q2 2026 holders
19
Q1 2025 holders
6
Holder diff
-13
| Investor | Q2 2026 Shares | Q1 2025 Shares | Share Diff | Share Chg % | Q2 2026 value | Q1 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend